SCHEMBL4032231

SCHEMBL4032231

COc1ccc(C(=O)c2cccc(Cl)c2F)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.50
RAB9A P51151 6/20 0.50
KMT2A Q03164 5/20 0.50
ALDH1A1 P00352 4/20 0.50
MEN1 O00255 3/20 0.50
HTT P42858 2/20 0.50
KCNH2 Q12809 1/20 0.50
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
SMN1; SMN2 Q16637 6/20 0.48
MAPT P10636 6/20 0.48
HPGD P15428 1/20 0.48
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
GLA P06280 1/20 0.45
POLB P06746 1/20 0.45
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4032358 0.90 RAB9A (0.54) NPC1RAB9AKMT2AALDH1A1HTT
SCHEMBL11575491 0.82 KMT2A (0.58) NPC1RAB9AKMT2AALDH1A1MEN1
SCHEMBL1407588 0.81 KMT2A (0.72) NPC1RAB9AKMT2AALDH1A1MEN1
SCHEMBL11814930 0.80 ALDH1A1 (0.55) NPC1RAB9AKMT2AALDH1A1MEN1
SCHEMBL8864729 0.80 ALDH1A1 (0.66) NPC1RAB9AKMT2AALDH1A1MEN1
SCHEMBL11575925 0.80 CYP1A2 (0.68) NPC1RAB9AKMT2AALDH1A1MEN1
SCHEMBL14601572 0.79 KMT2A (0.57) NPC1RAB9AKMT2AALDH1A1MEN1
SCHEMBL10623624 0.78 KMT2A (0.51) NPC1RAB9AKMT2AALDH1A1MEN1
SCHEMBL8180127 0.77 HTT (0.58) NPC1RAB9AKMT2AALDH1A1MEN1
SCHEMBL1408182 0.77 NPC1 (0.55) NPC1RAB9AKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US disclosed
EP-1542976-A1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES Wyeth (US) 2005-06-22 EP disclosed
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2004-08-26 US disclosed
WO-2004031159-A1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH (US) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR NPC1 3850/4885RAB9A 321/4885KMT2A 2656/4885
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols INSR, MSR1, TNNI3 NPC1 3636/4885RAB9A 930/4885KMT2A 2418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.